Clinical investigation of change of bone-related marker between denosumab and zoledronic acid in patients with treatment-naive,bone-metastasis prostate cancer:prospective, multiinstitutional,cohort study

Clinical investigation of change of bone-related marker between denosumab and zoledronic acid in patients with treatment-naive,bone-metastasis prostate cancer:prospective, multiinstitutional,cohort study - Comparative study between denosumab and zoledronic acid in terms of bone marker

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018268

Enrollment

Registered

2015-12-01

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

treatment-naive prostate cancer with bone metastasis

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: treatment naive prostate cancer with bone metastasis, recurrent prostate cancer due to bone metastasis,performance status under 2

Exclusion criteria

Exclusion criteria: history of radiation therapy to bone metastasis, history of dental treatment within 6 weeks of entry,Grade 4 renal insuffuciency such as eGFR under 30 or serum creatinine over 3

Design outcomes

Primary

Measure	Time frame
change of bone marker	—

Secondary

Measure	Time frame
adverse events, skeletal related event-free survival, PSA progression-free survival,change of renal function	—

Countries

Japan

Contacts

Public ContactJun-ichi Hori

Asahikawa Medical University Renal and Urologic Surgery

urohori@asahikawa-med.ac.jp0166-68-2533

Outcome results